Transcriptional profiling of lung adenocarcinomas has identified numerous gene expression phenotype (GEP) and risk prediction (RP) signatures associated with patient outcome. However, classification agreement between signatures, underlying transcriptional programs, and independent signature validation are less studied. We classified 2395 transcriptional adenocarcinoma profiles, assembled from 17 public cohorts, using 11 GEP and seven RP signatures, finding that 16 signatures were associated with patient survival in the total cohort and in multiple individual cohorts. For significant signatures, total cohort hazard ratios were ~2 in univariate analyses (mean=1.95, range=1.4-2.6). Strong classification agreement between signatures was observe...
Disease recurrence in surgically treated lung adenocarcinoma (AC) remains high. New approaches for r...
Disease recurrence in surgically treated lung adenocarcinoma (AC) remains high. New approaches for r...
Background The prognosis of patients for lung adenocarcinoma (LUAD) is known to vary widely; the 5-y...
Transcriptional profiling of lung adenocarcinomas has identified numerous gene expression phenotype ...
Purpose Primary lung adenocarcinoma remains a deadly disease. Gene expression phenotypes (GEPs) in a...
Although several prognostic signatures have been developed in lung cancer, their application in clin...
<div><p>Although several prognostic signatures have been developed in lung cancer, their application...
Although several prognostic signatures have been developed in lung cancer, their application in clin...
Although several prognostic signatures have been developed in lung cancer, their application in clin...
The 2021 WHO classification proposed a pattern-based grading system for early-stage invasive non-muc...
Abstract Background Several different gene expression signatures have been proposed to predict respo...
Background: Stage I lung adenocarcinoma is usually not treated with adjuvant chemotherapy; however, ...
Lung cancer remains the leading cause of cancer-related deaths worldwide. The recurrence rate ranges...
Background: Lung adenocarcinoma (LUAD) patients experiencing lymph node metastasis (LNM) always exhi...
Disease recurrence in surgically treated lung adenocarcinoma (AC) remains high. New approaches for r...
Disease recurrence in surgically treated lung adenocarcinoma (AC) remains high. New approaches for r...
Disease recurrence in surgically treated lung adenocarcinoma (AC) remains high. New approaches for r...
Background The prognosis of patients for lung adenocarcinoma (LUAD) is known to vary widely; the 5-y...
Transcriptional profiling of lung adenocarcinomas has identified numerous gene expression phenotype ...
Purpose Primary lung adenocarcinoma remains a deadly disease. Gene expression phenotypes (GEPs) in a...
Although several prognostic signatures have been developed in lung cancer, their application in clin...
<div><p>Although several prognostic signatures have been developed in lung cancer, their application...
Although several prognostic signatures have been developed in lung cancer, their application in clin...
Although several prognostic signatures have been developed in lung cancer, their application in clin...
The 2021 WHO classification proposed a pattern-based grading system for early-stage invasive non-muc...
Abstract Background Several different gene expression signatures have been proposed to predict respo...
Background: Stage I lung adenocarcinoma is usually not treated with adjuvant chemotherapy; however, ...
Lung cancer remains the leading cause of cancer-related deaths worldwide. The recurrence rate ranges...
Background: Lung adenocarcinoma (LUAD) patients experiencing lymph node metastasis (LNM) always exhi...
Disease recurrence in surgically treated lung adenocarcinoma (AC) remains high. New approaches for r...
Disease recurrence in surgically treated lung adenocarcinoma (AC) remains high. New approaches for r...
Disease recurrence in surgically treated lung adenocarcinoma (AC) remains high. New approaches for r...
Background The prognosis of patients for lung adenocarcinoma (LUAD) is known to vary widely; the 5-y...